Company intelligence

TSHA

Taysha Gene Therapies, Inc. · NASDAQ · Healthcare

Price$6.20+3.85% · +$0.23

Market cap1.98BEquity value

P / E-14.8Trailing ratio

Volume1.69MLatest session

Market data

TSHA price chart

TradingView

Related signals

1 min delayed

Browse public TSHA signals with their source context and measured market impact. Open any signal for its permanent analysis page.

TSHAMay 29, 2025-0.55% since signal

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

TSHA announced pivotal Part B trial for TSHA-102, following FDA guidance. 100% of patients gained developmental milestones; safety data shows mild effects. Underwritten public offering raised $200 million, priced at $2.75 per share. High-dose cohort showed superior outcomes compared to low-dose over time. TSHA stock increased 9%, reflecting positive trial news and funding success.

View signal analysis

TSHAMay 14, 2024+21.01% since signal

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates

- Taysha Gene Therapies reported quarterly loss of $0.10 per share, beating estimates. - Company revenue for the quarter ended March 2024 was $3.41 million, missing estimates. - Taysha's stock has outperformed the market, gaining 35.6% YTD. Price Impact Rating: bullish Impact Horizon Rating: short-term Type: Earnings

View signal analysis

Research